Large candidate gene association study reveals genetic risk factors and therapeutic targets for fibromyalgia
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Objective: Fibromyalgia (FM) represents a complex disorder that is characterized by widespread pain and tenderness and is frequently accompanied by additional somatic and cognitive/affective symptoms. Genetic risk factors are known to contribute to the etiology of the syndrome. The aim of this study was to examine >350 genes for association with FM, using a large‐scale candidate gene approach. Methods: The study group comprised 496 patients with FM (cases) and 348 individuals with no chronic pain (controls). Genotyping was performed using a dedicated gene array chip, the Pain Research Panel, which assays variants characterizing >350 genes known to be involved in the biologic pathways relevant to nociception, inflammation, and mood. Association testing was performed using logistic regression. Results: Significant differences in allele frequencies between cases and controls were observed for 3 genes: GABRB3 (rs4906902; P = 3.65 × 10−6), TAAR1 (rs8192619; P = 1.11 × 10−5), and GBP1 (rs7911; P = 1.06 × 10−4). These 3 genes and 7 other genes with suggestive evidence for association were examined in a second, independent cohort of patients with FM and control subjects who were genotyped using the Perlegen 600K platform. Evidence of association in the replication cohort was observed for TAAR1, RGS4, CNR1, and GRIA4. Conclusion: Variation in these 4 replicated genes may serve as a basis for development of new diagnostic approaches, and the products of these genes may contribute to the pathophysiology of FM and represent potential targets for therapeutic action.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nyholt, D. R. (2004) · The American Journal of Human Genetics · doi:10.1086/383251 · Cited by 1,699
Diatchenko, L., Slade, G. D., Nackley, A. G., Bhalang, K., Sigurdsson, A., Belfer, I., Goldman, D., Xu, K., Shabalina, S. A., Shagin, D., et al. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi013 · Cited by 1,280 · cited 6×
“54), nor the functional haplotypes of COMT (32).”
InfluentialSelf-citationFibromyalgia and overlapping disorders: The unifying concept of central sensitivity syndromes
Yunus, M. B. (2007) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2006.12.009 · Cited by 780
Arnold, L. M., Hudson, J. I., Hess, E. V., Ware, A. E., Fritz, D. A., Auchenbach, M. B., Starck, L. O., & Keck, P. E. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20042 · Cited by 454
Giesecke, T., Williams, D. A., Harris, R. E., Cupps, T. R., Tian, X., Tian, T. X., Gracely, R. H., & Clauw, D. J. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11272 · Cited by 424
Self-citationIdiopathic pain disorders – Pathways of vulnerability
Diatchenko, L., Nackley, A. G., Slade, G. D., Fillingim, R. B., & Maixner, W. (2006) · Pain · doi:10.1016/j.pain.2006.04.015 · Cited by 398
Self-citationNabilone for the treatment of pain in fibromyalgia.
Skrabek, R. Q., Galimova, L., Ethans, K., & Perry, D. (2008) · The Journal of Pain · doi:10.1016/j.jpain.2007.09.002 · Cited by 384 · cited 1×
“The analgesic properties of the CB-1 cannabinoid receptor encoded by CNR1 have been well-documented, and the cannabinoid agonist nabilone has demonstrated improvements in pain and life quality in patients with FM (39).”
Poor replication of candidate genes for major depressive disorder using genome-wide association data
Bosker, F. J., Hartman, C. A., Nolte, I. M., Prins, B. P., Terpstra, P., Posthuma, D., van Veen, T., Willemsen, G., DeRijk, R. H., de Geus, E. J., et al. (2011) · Molecular Psychiatry · doi:10.1038/mp.2010.38 · Cited by 309
Understanding fibromyalgia: lessons from the broader pain research community.
Williams, D. A., & Clauw, D. J. (2009) · The Journal of Pain · doi:10.1016/j.jpain.2009.06.001 · Cited by 250 · cited 1×
“Other complaints and symptoms, such as affective distress, hyperalgesia and allodynia, cognitive disturbance, and gastrointestinal disruption frequently accompany the pain, and the diagnosis of FM is often comorbid with other functional syndromes such as irritable bowel syndrome (IBS), temporomandibular joint disease…”
Trace Amine-Associated Receptors as Emerging Therapeutic Targets
Sotnikova, T. D., Caron, M. G., & Gainetdinov, R. R. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.055970 · Cited by 97 · cited 1×
“This receptor presents an interesting target for the development of novel TAAR-selective compounds with analgesic properties (35).”
Cited by
Fibromyalgia: an update on clinical characteristics, aetiopathogenesis and treatment
Sarzi-Puttini, P., Giorgi, V., Marotto, D., & Atzeni, F. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-00506-w · Cited by 793
Fibromyalgia: Pathogenesis, Mechanisms, Diagnosis and Treatment Options Update
Siracusa, R., Paola, R. D., Cuzzocrea, S., & Impellizzeri, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22083891 · Cited by 659
AAPT Diagnostic Criteria for Fibromyalgia
Arnold, L. M., Bennett, R. M., Crofford, L. J., Dean, L. E., Clauw, D. J., Goldenberg, D. L., Fitzcharles, M.-A., Paiva, E. S., Staud, R., Sarzi-Puttini, P., et al. (2019) · The Journal of Pain · doi:10.1016/j.jpain.2018.10.008 · Cited by 420
Fitzcharles, M.-A., Ste-Marie, P. A., Goldenberg, D. L., Pereira, J. X., Abbey, S., Choinière, M., Ko, G., Moulin, D. E., Panopalis, P., Proulx, J., et al. (2013) · Pain Research and Management · doi:10.1155/2013/918216 · Cited by 409
The neurobiology of central sensitization
Harte, S. E., Harris, R. E., & Clauw, D. J. (2018) · Journal of Applied Biobehavioral Research · doi:10.1111/jabr.12137 · Cited by 394
Trace Amines and Their Receptors
Gainetdinov, R. R., Hoener, M. C., & Berry, M. D. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015305 · Cited by 384
Pain genetics: past, present and future
Mogil, J. S. (2012) · Trends in Genetics · doi:10.1016/j.tig.2012.02.004 · Cited by 321
Abnormal endogenous pain modulation is a shared characteristic of many chronic pain conditions
Staud, R. (2012) · Expert Review of Neurotherapeutics · doi:10.1586/ern.12.41 · Cited by 290
Fibromyalgia: A Critical and Comprehensive Review
Borchers, A. T., & Gershwin, M. E. (2015) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-015-8509-4 · Cited by 275
Central sensitization in humans: assessment and pharmacology
Arendt-Nielsen, L. (2015) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-662-46450-2_5 · Cited by 125
“Furthermore, genetic factors (Smith et al. 2011, 2012) and cognitive, social, and lifestyle factors (Mourão et al. 2010) may be important.”
BackgroundProfile of Cerebrospinal microRNAs in Fibromyalgia
Bjersing, J. L., Lundborg, C., Bokarewa, M. I., & Mannerkorpi, K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078762 · Cited by 98
Hung, C.-H., Lee, C.-H., Tsai, M.-H., Chen, C.-H., Lin, H.-F., Hsu, C.-Y., Lai, C.-L., & Chen, C.-C. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-218329 · Cited by 65
Physical and mental impact of COVID-19 outbreak on fibromyalgia patients
Aloush, V., Gurfinkel, A., Shachar, N., Ablin, J. N., & Elkana, O. (2021) · Clinical and Experimental Rheumatology · doi:10.55563/clinexprheumatol/rxk6s4 · Cited by 45
Fibromyalgia: are you a genetic/environmental disease
Ablin, J. N. (2025) · PAIN Reports · doi:10.1097/pr9.0000000000001256 · Cited by 7
“1,26,27,64,68 More recently evolving tools such as machine learning (ML) are being harnessed in the attempt to analyze these vast data sets of genetic information.”
Metadata
- Authors
- Smith, S. B., Maixner, D. W., Fillingim, R. B., Slade, G., Gracely, R. H., Ambrose, K., Zaykin, D. V., Hyde, C., John, S., Tan, K., Maixner, W., & Diatchenko, L.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2012-01-27
- Volume
- 64
- Issue
- 2
- Pages
- 584-593
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2122756645
- Cited by
- 106
- References
- 10
- FWCI
- 5.12
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.